Most recent by Patrick C. Ma, MD, MSc
SPONSORED CONTENT
January 10, 2019
5 min read
Save
‘Cancer-agnostic’ NTRK inhibitor approval ushers in paradigm of personalized genomics-guided therapeutics
On Nov. 26, the FDA announced the accelerated approval of larotrectinib as the first small molecule inhibitor for use in a “cancer-agnostic” manner, in pediatric and adult human cancers that harbor neurotrophic receptor tyrosine kinase gene fusions.
SPONSORED CONTENT
April 01, 2013
3 min read
Save
ALK-targeted therapeutics represent ‘profound revolution’ in personalized cancer therapy
Albert Einstein once said: “Learn from yesterday, live for today, hope for tomorrow. The important thing is not to stop questioning.”